

EMA/144932/2021

European Medicines Agency decision P/0091/2021

of 17 March 2021

on the acceptance of a modification of an agreed paediatric investigation plan for palbociclib (Ibrance), (EMA-002146-PIP01-17-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0091/2021

of 17 March 2021

on the acceptance of a modification of an agreed paediatric investigation plan for palbociclib (Ibrance), (EMA-002146-PIP01-17-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0209/2018 issued on 17 July 2018 and the decision P/0203/2019 issued on 12 June 2019,

Having regard to the application submitted by Pfizer Europe MA EEIG on 21 October 2020 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 29 January 2021, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for palbociclib (Ibrance), capsule, hard, age-appropriate oral dosage form, film-coated tablet, oral use, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 – Brussels, Belgium.

EMA/PDCO/579754/2020 Corr
Amsterdam, 29 January 2021

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-002146-PIP01-17-M02

Scope of the application

Active substance(s):

Palbociclib

Invented name:

Ibrance

Condition(s):

Treatment of Ewing sarcoma

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Capsule, hard

Age-appropriate oral dosage form

Film-coated tablet

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Pfizer Europe MA EEIG

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Pfizer Europe MA EEIG submitted to the European Medicines Agency on 21 October 2020 an application for modification of the agreed paediatric investigation plan with a waiver as set out in the European Medicines Agency's decision P/0209/2018 issued on 17 July 2018 and the decision P/0203/2019 issued on 12 June 2019.

The application for modification proposed changes to the agreed paediatric investigation plan.

The procedure started on 1 December 2020.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of Ewing sarcoma

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- capsule, hard, age-appropriate oral dosage form, film-coated tablet, oral use;
- on the grounds that clinical studies with the specific medicinal product cannot be expected to be of significant therapeutic benefit to or fulfil a therapeutic need of the specified paediatric subset(s).

2. Paediatric investigation plan

2.1. Condition:

Treatment of Ewing sarcoma

2.1.1. Indication(s) targeted by the PIP

In combination with topotecan and cyclophosphamide for the treatment of patients from 2 years to less than 18 years of age with refractory or recurrent Ewing sarcoma

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Capsule, hard

Age-appropriate oral dosage form

Film-coated tablet

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	Study 1 Development of an oral solution formulation for paediatric patients unable to swallow the capsules
Non-clinical studies	2	Study 2 In vivo study to assess the anti-tumour activity of palbociclib used in combination with irinotecan and temozolomide compared irinotecan and temozolomide alone in Ewing sarcoma xenografts

		Study 3 In vitro study to evaluate the anti-tumour activity of palbociclib used in with irinotecan in Ewing sarcoma (EWS) cell lines
Clinical studies	2	Study 4 Open-label, single-arm dose-escalation trial to evaluate the safety, pharmacokinetics and anti-tumour activity of palbociclib used in combination with temozolomide and irinotecan and in combination with topotecan and cyclophosphamide in children from 2 years to less than 18 years of age (and young adults) with a recurrent or refractory solid tumour with a dose-finding phase (dose-escalation and dose determination parts) and an expansion cohorts (dose expansion parts) (A5481092) Study 5 Open-label, randomised controlled trial to evaluate the efficacy, safety and pharmacokinetics of palbociclib used in combination with topotecan and cyclophosphamide as compared to temozolomide and irinotecan alone in children from 2 years to less than 18 years of age (and adults) with recurrent and /or refractory Ewing sarcoma (rEECur, palbociclib in combination with topotecan and cyclophosphamide arm)
Extrapolation, modelling and simulation studies	0	Not applicable
Other studies	0	Not applicable
Other measures	0	Not applicable

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By April 2025
Deferral for one or more measures contained in the paediatric investigation plan:	No

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of breast malignant neoplasms

Authorised indication(s):

- IBRANCE is indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer:
 - in combination with an aromatase inhibitor;
 - in combination with fulvestrant in women who have received prior endocrine therapy.

In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.

Authorised pharmaceutical form(s):

Capsule, hard

Film-coated tablet

Authorised route(s) of administration:

Oral use